MeiraGTx posts investor deck outlining late-stage gene therapy pipeline, manufacturing platform

MEIRAGTX HOLDINGS PLC

MEIRAGTX HOLDINGS PLC

MGTX

0.00
  • MeiraGTx highlighted four late-stage programs, led by AAV-AQP1 for radiation-induced xerostomia with a potential BLA filing in mid-2027.
  • AAV-AQP1 launch target set for early 2028; management cited a large addressable market with estimated global annual peak sales of USD 3.7 billion.
  • X-linked retinitis pigmentosa program completed Phase 3; BLA and MAA described as ready with process performance qualification complete.
  • AAV-AIPL1 congenital blindness program positioned for near-term FDA and MHRA filings; potential approvals flagged for 2026.
  • Partnership updates included Eli Lilly collaboration with USD 75 million upfront cash, up to USD 135 million near-term AAV-AIPL1 milestones, tiered royalties, and a USD 200 million Hologen JV payment.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MeiraGTx Holdings plc published the original content used to generate this news brief on June 05, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.